News stories about Gemphire Therapeutics (NASDAQ:GEMP) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Gemphire Therapeutics earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.4670250934484 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Several equities analysts have weighed in on the company. Zacks Investment Research lowered Gemphire Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, August 17th. Canaccord Genuity set a $31.00 price objective on Gemphire Therapeutics and gave the company a “buy” rating in a report on Tuesday, August 8th. Jefferies Group LLC increased their price objective on Gemphire Therapeutics to $32.00 and gave the company a “buy” rating in a report on Tuesday, August 1st. Finally, HC Wainwright began coverage on Gemphire Therapeutics in a report on Thursday, August 31st. They set a “buy” rating and a $21.00 price objective for the company. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $24.50.

Gemphire Therapeutics (GEMP) traded up 1.3814% during trading on Wednesday, hitting $9.2764. The stock had a trading volume of 64,639 shares. Gemphire Therapeutics has a 52-week low of $7.25 and a 52-week high of $12.99. The company’s market cap is $98.57 million. The company has a 50-day moving average price of $9.75 and a 200-day moving average price of $9.44.

Gemphire Therapeutics (NASDAQ:GEMP) last announced its earnings results on Monday, August 14th. The company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.28). Equities research analysts forecast that Gemphire Therapeutics will post ($3.18) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Daily Political and is the property of of Daily Political. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at

Gemphire Therapeutics Company Profile

Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.

Insider Buying and Selling by Quarter for Gemphire Therapeutics (NASDAQ:GEMP)

Receive News & Ratings for Gemphire Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics Inc. and related companies with's FREE daily email newsletter.